Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$31.6 million.

  • Vanda Pharmaceuticals' Cash from Operations fell 11689.87% to -$31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.8 million, marking a year-over-year decrease of 36311.68%. This contributed to the annual value of -$15.8 million for FY2024, which is 22309.19% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Cash from Operations stood at -$31.6 million for Q3 2025, which was down 11689.87% from -$15.3 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Cash from Operations registered a high of $31.8 million during Q1 2023, and its lowest value of -$33.1 million during Q1 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' median Cash from Operations value was $4.0 million (recorded in 2022), while the average stood at $695631.6.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Cash from Operations skyrocketed by 111356.12% in 2021, and later plummeted by 61126.83% in 2024.
  • Over the past 5 years, Vanda Pharmaceuticals' Cash from Operations (Quarter) stood at $26.6 million in 2021, then tumbled by 64.61% to $9.4 million in 2022, then crashed by 139.63% to -$3.7 million in 2023, then soared by 51.31% to -$1.8 million in 2024, then crashed by 1640.56% to -$31.6 million in 2025.
  • Its Cash from Operations stands at -$31.6 million for Q3 2025, versus -$15.3 million for Q2 2025 and -$33.1 million for Q1 2025.